Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from M3 ( (JP:2413) ).
M3, Inc. has disclosed the latest status of its ongoing share repurchase program authorized by its board in May 2025 under Article 459 of Japan’s Companies Act. Between December 1 and December 31, 2025, the company repurchased 160,400 common shares on the Tokyo Stock Exchange via discretionary trades for a total of ¥348.27 million, bringing cumulative buybacks under the current authorization as of December 31, 2025 to 1,760,500 shares for approximately ¥3.65 billion. This remains well within the approved ceiling of up to 20 million shares or ¥20 billion through April 30, 2026, signaling that M3 still has substantial capacity to continue buybacks as a tool for capital allocation and shareholder return, while retaining flexibility to adjust activity depending on market conditions.
The most recent analyst rating on (JP:2413) stock is a Buy with a Yen2760.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
More about M3
M3, Inc., listed on the Tokyo Stock Exchange Prime Market under ticker 2413 and headquartered in Tokyo’s Minato ward, operates in the healthcare and medical information services sector, leveraging online platforms and related solutions to connect medical professionals, healthcare institutions, and industry partners.
Average Trading Volume: 3,507,484
Technical Sentiment Signal: Sell
Current Market Cap: Yen1435.6B
For a thorough assessment of 2413 stock, go to TipRanks’ Stock Analysis page.